Laurentius Ziekenhuis Roermond
- Address
- Monseigneur Driessenstraat 6, 6043 CV Roermond, The Netherlands
Laurentius Ziekenhuis Roermond - Oncology and Multi-Specialty Clinical Research Center
Laurentius Ziekenhuis Roermond is a comprehensive clinical research center with a strong emphasis on oncology clinical trials and innovative cancer treatment strategies. The center demonstrates particular expertise in gastrointestinal and breast cancer research, conducting studies that evaluate novel therapeutic approaches, treatment sequencing strategies, and organ-preservation techniques. Their research portfolio reflects a commitment to advancing personalized medicine and improving quality of life for cancer patients through evidence-based treatment protocols.
- Breast Cancer Research: Advanced studies in hormone receptor-positive and HER2-positive breast cancer, including CDK4/6 inhibitor strategies, targeted therapy combinations, and image-guided treatment de-escalation
- Gastrointestinal Oncology: Innovative trials in rectal cancer preservation, esophagogastric cancer immunotherapy, and metastatic colorectal cancer treatment optimization
- Hematologic Malignancies: Multiple myeloma treatment strategies exploring treatment-free intervals and novel therapeutic combinations
- Respiratory and Cardiovascular Medicine: Platform trials for community-acquired pneumonia, COPD management, and cardiovascular prevention studies
Beyond oncology, the center participates in diverse therapeutic research areas including chronic kidney disease, thyroid disorders, and prostate cancer. Their involvement in adaptive platform trials and randomized controlled studies demonstrates a sophisticated approach to clinical research methodology. The center's participation in international multi-center trials positions it as an important contributor to global evidence generation across multiple medical specialties, with particular focus on treatment optimization, toxicity reduction, and patient-centered outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 12 therapeutic areas and 15 of 66 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 64 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
- 1Amsterdam UMC Stichting2active
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amsterdam UMC Stichting5trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Laurentius Ziekenhuis Roermond
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Adjuvant Pembrolizumab Versus Capecitabine or Olaparib in Patients with Early-Stage Triple-Negative Breast Cancer with Residual Disease Following Neoadjuvant Therapy | Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | Phase III | Recruiting | Jul 2026 | — |
IMP list
lock Showing 1 of 66 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 5 | Unknown | 2017-06-16 | 2026-07-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.